JIR
EBS icon

James Investment Research’s Emergent Biosolutions EBS Stock Holding History

James Investment Research’s Portfolio EBS Stock Details EBS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$519K Hold
61,963
– – 0.05% 263
2026
Q1 		$514K Buy
61,963
+64
+0.1% +$663 0.06% 250
2025
Q4 		$765K Buy
+61,899
New +$663K 0.08% 192
2018
Q2 		– Sell
-44,263
Closed -$2.33M – 814
2018
Q1 		$2.33M Buy
+44,263
New +$2.21M 0.09% 230

Other funds holding EBS

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
LSV Asset Management
LSV Asset Management Chicago, Illinois $55.1B AUM 45.38% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Charles Schwab
Charles Schwab San Francisco, California $751B AUM 38.74% 1-Year Est. Return
OHA
Oak Hill Advisors New York $701M AUM 78.4% 1-Year Est. Return

James Investment Research's EBS Position: Q2 2026 in Review

James Investment Research held its Emergent Biosolutions (EBS) position steady in Q2 2026 at 61,963 shares worth $519K. The position accounts for 0.05% of the portfolio, ranked #263.

James Investment Research first reported a position in EBS in Q1 2018 and has held it in 4 quarters since. The position peaked at $2.33M in Q1 2018. 195 funds tracked by Wall St. Rank hold EBS as of Q2 2026.

  • James Investment Research held 61,963 shares of Emergent Biosolutions worth $519K as of Q2 2026.
  • James Investment Research left its Emergent Biosolutions share count unchanged in Q2 2026.
  • Emergent Biosolutions made up 0.05% of James Investment Research's portfolio in Q2 2026, its #263 holding.
  • James Investment Research first reported a position in Emergent Biosolutions in Q1 2018 and has held it in 4 quarters since.
  • James Investment Research's Emergent Biosolutions position peaked at $2.33M in Q1 2018.
  • 195 funds tracked by Wall St. Rank held Emergent Biosolutions as of Q2 2026.

Based on James Investment Research's 13F filing for Q2 2026, filed 24 Jul 2026.